Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Nov 02, 2022
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Oct 31, 2022
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid
Oct 26, 2022
AIM ImmunoTech Board Issues Letter to Shareholders
Oct 12, 2022
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Sep 21, 2022
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
Sep 19, 2022
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
Sep 07, 2022
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 06, 2022
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Aug 30, 2022
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
Aug 18, 2022
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
3
4
5
6
7
8
9
10
11
12
13
<<
<
>
>>
Privacy